Dr. Erin Larkins is a Team Lead for the Thoracic and Head & Neck Tumors Team in the Office of Oncologic Diseases at FDA. After obtaining her degree in Molecular Biochemistry and Biophysics at Yale University, Dr. Larkins attended medical school at the Uniformed Services University of the Health Sciences as a Naval officer, graduating in 2000. She completed residency training in Internal Medicine at the Bethesda Naval Hospital followed by fellowship training in Medical Oncology and Hematology at the National Cancer Institute in Bethesda, MD. She served as a medical oncologist in the U.S. Navy for 8 years and was the Associate Program Director for the National Capital Consortium Hematology-Oncology fellowship program from 2011 to 2014. In 2014, Dr. Larkins transferred to the US Public Health Service and came to work at the Federal Drug Administration (FDA) as a clinical reviewer for the Thoracic and Head & Neck Tumors Team. She became a Team Lead for the Thoracic and Head & Neck Tumors Team in 2017. She continues to provide clinical care to patients with lung and head & neck cancer as a volunteer at Walter Reed National Military Medical Center.

Born Freeport, NY Graduated BUSM 1981 Residency - Graduate Hospital of the University of PA; '81-84 Fellowship - PUPMC: '84-'86 AOH/Fox Chase: '86-'87 Staff: Fox Chase Cancer Center: '87-'08 Director of Thoracic Oncology and Professor of Medicine: University of Pennsylvania: since 2008 Editor: IASLC News

Assistant Professor, Thoracic Oncology

Dr. Victoria Lai is a clinical and translational investigator in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York, NY, USA. Her research focus is on small cell lung cancer and other pulmonary neuroendocrine diseases.

David Kozono, MD, PhD, is a Senior Physician in Dana-Farber's Lowe Center for Thoracic Oncology and Assistant Professor of Radiation Oncology at Harvard Medical School. His clinical and research focus is on precision radiotherapy and multimodality therapy for lung cancer. He serves as the Co-Chair of the Immuno-Oncology Committee and Executive Officer for the Respiratory Committee of the Alliance for Clinical Trials in Oncology. In these roles he participates in the development and conduct of nationwide clinical trials testing novel targeted therapies and immunotherapy for lung cancer.

Edward S. Kim, MD, MDA is senior vice president and physician-in-chief at City of Hope Orange County and vice physician-in-chief at City of Hope National Medical Center. Recently, Dr. Kim served as chairman of Solid Tumor Oncology and Investigational Therapeutics and medical director of clinical trials at Levine Cancer Institute, Atrium Health, Charlotte, NC. Prior, he was tenured associate professor in thoracic/head and neck medical oncology at University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Kim completed his MBA at University of North Carolina Keenan-Flagler School of Business.

Dr. Fadlo R. Khuri is the 16th president of the American University of Beirut (AUB) and professor of medicine at the Faculty of Medicine and Medical Center.

Khuri is an accomplished molecular and translational oncologist, having authored over 750 publications. He serves as Editor in Chief of the journal Cancer. Prior to AUB, he was a professor and executive associate dean for research at Emory University School of Medicine and deputy director of the Winship Cancer Institute. Khuri was born in Boston and raised in Beirut. He earned his undergraduate degree at Yale University and MD at Columbia University College of Physicians and Surgeons.

Under Khuri’s leadership, AUB has reintroduced academic tenure and initiated several new PhD programs. He has helped obtain grants and donations for underprivileged students and patients totaling more than $250 million. In 2018, he spearheaded the effort to declare AUB a fully tobacco-free campus.

Khuri is leading the $650 million BOLDLY AUB capital campaign, which brought in the largest single gift in the university’s history. He also developed a new campus master plan and strategic plan: VITAL 2030. Khuri is a fellow of the American College of Physicians and his work has been recognized with several major awards.

Karen Kelly, MD, FASCO is the Associate Director of Clinical Research at UC Davis and the Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research. Dr. Kelly received her medical degree from the University of Kansas School of Medicine.  She completed her internship and residency at the University of Colorado Health Sciences Center and completed her fellowship in medical oncology at the University of Colorado Health Sciences Center.

Dr. Kelly is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Dr. Kelly’s lung cancer research spans the spectrum of the disease from prevention to treatment. She has been at the forefront of clinical trials development evaluating drugs to treat lung cancer and novel compounds to prevent lung cancer. She is also involved in developing biomarkers for screening and early detection of lung cancer.

Dr. Kelly has authored or co-authored more than 190 publications, including original papers, reviews and book chapters. She frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly is a long-standing active member of ASCO, IASLC and SWOG and currently serves as the SWOG Lung Committee Chair.

Dr. Kalemkerian is Professor of Medicine in the Division of Hematology/Oncology at University of Michigan. He currently serves as the Associate Division Chief for Faculty Development and Education, Associate Director of the Hematology/Oncology Fellowship Program, and Co-Director of the Thoracic Oncology Clinical Research Team. Clinically, he cares for people with lung cancer, thymoma, and mesothelioma, and his academic research interest is clinical and translational trials for thoracic cancers.

Dr. Kalemkerian received his undergraduate and medical degrees from Northwestern University. He then completed his residency in Internal Medicine at Northwestern Memorial Hospital and a fellowship in Medical Oncology at the Johns Hopkins Hospital. He was a physician-scientist at Wayne State University/Karmanos Cancer Institute from 1993-1999, and has been on faculty at the University of Michigan since 1999.

Dr. Kalemkerian’s honors include the receipt of the University of Michigan Outstanding Clinician Award and the ASCO Excellence in Teaching Award. Dr. Kalemkerian has given over 200 invited lectures, authored more than 175 research articles, reviews and book chapters, and edited two books on lung cancer.

Dr. Juergens received her medical degree from Georgetown University in Washington, D.C.  She was an intern and resident in the Osler Internal Medicine Training Program at The Johns Hopkins Medical Institute.  She completed a fellowship in medical oncology with a focus on upper aerodigestive malignancies as well at Johns Hopkins.  Additionally, she completed her Ph.D. in Clinical Investigation at The Johns Hopkins Bloomberg School of Public Health.  She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University. Dr. Juergens’ clinical expertise is in lung and esophageal cancer. She chairs the Lung Disease Site Team at the Juravinski Cancer Centre in Hamilton, Ontario.  She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre.  She is a member of the Escarpment Cancer Research Institute. Her research focus has been in developmental therapeutics with a concentration on Phase I and II clinical trials. She is the chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee.